Table 1

Demographics and clinical parameters of 118 patients with rheumatoid arthritis (RA)

Baseline characteristicsNo. of patients
Mean (SD) age at delivery, years32.3 (3.6)
Median (range) disease duration at delivery, years5.7 (0.7–29.7)
Patients with disease duration <2 years, % (n)16 (19)
Anti-CCP present, % (n)62 (73)
RF present, % (n)74 (87)
    IgM-RF73 (86)
    IgG-RF33 (39)
    IgA-RF35 (41)
Erosions present, % (n)70 (81)
DAS28 CRP 3>3.2 in first trimester, % (n)61 (72)
Classification of disease activity during pregnancy
    Good response/moderate response, % (n)47 (34)*
    no response, % (n)53 (38)*
Classification of disease activity post partum
    severe deterioration/moderate deterioration, % (n)36 (42)
    no deterioration, % (n)64 (76)
Use of methotrexate prior to wish to conceive, % (n)58 (68)
Use of (oral) prednisone use prior to pregnancy, % (n)43 (50)
Use of biologicals prior to wish to conceive, % (n)10 (12)
Mean number of DMARDs and biologicals ever used prior to wish to conceive, n (SD)2.5 (1.5)
  • *Of 72 patients with DAS28 CRP 3>3.2 in first trimester.

  • CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying antirheumatic drug; RF, rheumatoid factor.